The current development status of the global and Chinese small molecule anti-tumor targeted drug industry

China is a major cancer country in the world. The main types of malignant cancer in China are lung cancer, gastric cancer, colorectal cancer, liver cancer, breast cancer and esophageal cancer. The high incidence and death of cancer patients has created a huge demand for innovative therapeutic drugs and treatment schemes. From the perspective of the overall Chinese market, the market size of small molecule anti-tumor drugs in China will reach 73.4 billion yuan in 2023, and it is expected to further grow to 207.5 billion yuan in 2030. The compound annual growth rate during this period is 16.0%, far exceeding the global level during the same period, demonstrating the strong growth momentum of the Chinese market.

Representative enterprise of China's small molecule anti-tumor targeted drug industry - Zhejiang Tongtongkang Pharmaceutical

From the perspective of corporate advantages: In August 2024, as the 66th biotechnology company listed on the Hong Kong Stock Exchange under Rule 18A, Tongyuan Kang quickly completed the listing process in less than 7 months, and is expected to become the largest company in terms of issuance scale among similar enterprises in 2024. This not only demonstrates the company's operational efficiency, but also reflects the high recognition and expectations of the social capital market for Tongyuan Kang Pharmaceutical.

In terms of technological advantages, Tongyuan Kang has leading research and development progress and a differentiated product pipeline, focusing on the research and development of the best drugs in the market. Its core product TY-9591 is the only EGFR-TKI in the world that has been compared with osimertinib in head to head clinical trials.

From the perspective of track advantages: with the increase of incidence rate of cancer and the growth of demand for precision medicine, targeted drugs have gradually become the preferred treatment scheme. The diversification of small molecule anti-tumor targeted drug products and broad market prospects provide huge market potential and growth opportunities for Tongyuan Kang Pharmaceutical.

Www.eastmoney.com August 30, 2024 Head Leopard Research Institute View PDF Origina